Sanofi shares slip as FDA halts trial for erectile dysfunction drug

Euroapi SA

30/05/2022 08:53

** Shares in Sanofi  SASY.PA  fall 2.7% to the bottom of
Fance's CAC 40 index  .FCHI  after the drugmaker said the U.S.
FDA had placed an actual use trial of its Cialis treatment on
clinical hold  urn:newsml:reuters.com:*:nL1N2XM0A1
    ** An analyst points to low market expectations to explain
the share move, but adds the trial was supposed to boost the
group's consumer healtcare division sales in case of success
    ** "Sanofi continues to work with the FDA to move the Cialis
program forward," the company says, adding the next steps will
be determined in upcoming meetings
    ** On hold "due to matters surrounding the protocol design",
Cialis is a tablet taken to treat erectile dysfunction, the
signs and symptoms of benign prostatic hyperplasia
    ** "It is a bit surprising to sop a trial before its start,
especially as the protocol is usually agreed in advance," the
analyst also flags in an email
    ** Separately, drug ingredients business spun off from
Sanofi, EuroAPI  EAPI.PA , says it will support the company's
mRNA vaccine platform with lipid nanoparticles development
 urn:newsml:reuters.com:*:nASM000DNY
    ** The stock of Sanofi is up by about 13% year-to-date

 (Reporting by Juliette Portala)
 ((juliette.portala@tr.com))